Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL.
Experimental low density lipoprotein (LDL) oxidation is usually performed using trace copper, although the in vivo relevance of this method has been called into question. Such LDL augment adenosine 5'-diphosphate (ADP) induced platelet aggregation, presumably by the action of lipid derived compounds. In striking contrast, we find that LDL oxidized to a comparable extent by hypochlorite, an in vivo occurring oxidant, reveal themselves to be potent promoters of platelet aggregation. Interestingly, hypochlorite modified LDL seem to mediate their influence on human platelets by means of the modified apolipoprotein B-100 (apoB) moiety. Also, the finding that hypochlorite modified albumin is able to trigger platelet aggregation suggests an essential role for hypochlorite modified protein(s) in the process of platelet activation.
Volf
I
I
Institute of Physiology, Schwarzspanierstr. 17, A-1090 Vienna, Austria. ivo.wolf@univie.ac.at
Roth
A
A
Cooper
J
J
Moeslinger
T
T
Koller
E
E
D001667:Binding, Competitive; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003300:Copper / Q000737:chemistry*; D006801:Humans; D006997:Hypochlorous Acid / Q000737:chemistry*; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*; D010084:Oxidation-Reduction; D010974:Platelet Aggregation / Q000187:drug effects*
D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D006997:Hypochlorous Acid; D003300:Copper